Skip to main content

Japanese biotech pays Albireo $135M for local liver disease drug rights

Japanese biotech Jadeite Medicines is paying Boston-based Albireo Pharma Inc. up to $135 million for Japanese rights to Bylvay, the company's recently approved drug for rare liver diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.